A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Pharmacokinetics, Efficacy, and Safety of Gabapentin Enacarbil in Subjects With Restless Legs Syndrome
Clinical Neuropharmacology, 07/27/2012Lal R et al.
Gabapentin exposure was approximately proportional to gabapentin enacarbil (GEn) dose. Efficacy data showed that a once–daily dose of GEn 600 to 2400 mg provides greater relief of restless legs syndrome (RLS) symptoms than placebo; GEn was generally well tolerated with an adverse event profile consistent with gabapentin.
Subjects with RLS (n=217) were randomized to receive once-daily, orally administered GEn 600 (n=48), 1200 (n=45), 1800 (n=38), or 2400 mg (n=45) or placebo (n=41) in this 12-week, double-blind, multicenter study (NCT01332305).
Clinic visits were at screening, baseline, and weeks 1, 2, 3, 4, 6, 8, 10, and 12; plasma gabapentin concentrations were measured by a validated liquid chromatography-mass spectrometry/mass spectrometry method at weeks 4 and 12.
Exposure to gabapentin was proportional to GEn dose.
Time to maximum plasma concentration was 7 to 9 hours, and elimination half-life was 6 hours.
The mean reduction from baseline to week 12 in International Restless Legs Syndrome Rating Scale total score and proportions of subjects with “much improved”/“very much improved” Clinical Global Impression-Improvement scores (investigator and patient ratings) ranged from -12.9 to -13.9 for GEn treatment groups versus -9.3 for placebo.
The 2 most commonly reported adverse events were somnolence and dizziness.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.